07:11 AM EDT, 08/26/2024 (MT Newswires) -- BeiGene ( BGNE ) said Monday that BGB-16673, received a fast track designation from the US Food and Drug Administration for potentially treating relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

The designation, with support from phase 1/2 safety and efficacy data, is to expedite FDA's review of BGB-16673 as a treatment for adults with CLL or SLL that has relapsed or did not respond to initial treatment, according to BeiGene ( BGNE ).

Shares of the company were up 2.8% in recent Monday premarket activity.

Price: 199.23, Change: +5.41, Percent Change: +2.79